- ProMed Pharma has acquired a 28,000 square foot pharmaceutical manufacturing facility in Plymouth, Minnesota, from Bora Pharmaceuticals.
- The site will expand commercial manufacturing capacity and is expected to be fully operational by mid-2026.
ProMed Pharma LLC, a provider of polymer-based drug delivery solutions, has acquired a 28,000 square foot pharmaceutical manufacturing facility in Plymouth, Minnesota. The site, formerly owned and operated by Bora Pharmaceuticals, adds to ProMed Pharma’s commercial manufacturing capabilities.
The acquisition is aimed at strengthening the company’s position in complex drug delivery systems and supporting its growing base of pharmaceutical and biotech partners. The facility includes controlled warehousing, Grade C and D manufacturing space, and expansion capacity. It also offers GMP-compliant infrastructure that complements ProMed Pharma’s existing operations.
Clint Schneider, President of ProMed Pharma, said: “The acquisition of this facility marks a significant milestone in our growth strategy. It not only increases our production capacity but also strengthens our position as a trusted CDMO partner in the development and manufacture of controlled release and combination drug-device products.”
The company stated that the facility is expected to be fully operational by mid-2026. ProMed Pharma continues to focus on the development and manufacture of polymer-based dosage forms, including drug-releasing implants and combination devices.
